<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2023-5-49-52</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-3072</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Псориаз с поражением кожи лица, возникшим на фоне отмены иксекизумаба (клинический случай)</article-title><trans-title-group xml:lang="en"><trans-title>Psoriasis with facial skin lesions that arose against background of withdrawal of ixekizumab (clinical case)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3798-3341</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Владимирова</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Vladimirova</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владимирова Ирина Сергеевна - кандидат медицинских наук, ассистент кафедры инфекционных болезней, эпидемиологии и дерматовенерологии Санкт-Петербургский ГУ, старший преподаватель кафедры кожных и венерических болезней ВМА имени С. М. Кирова, врач-дерматовенеролог Кожно-венерологический диспансер № 10 – КДВ.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Vladimirova Irina S. - PhD Med, Assistant at Dept of Infectious Diseases, Epidemiology and Dermatovenereology Saint Petersburg SU, senior lecturer of Dept of Skin and Venereal Diseases MMA n. a. S. M. Kirov, Dermatovenereologist Dispensary No. 10 –CDV.</p><p>Saint Petersburg</p></bio><email xlink:type="simple">ivladimirva@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8584-615X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнова</surname><given-names>И. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnova</surname><given-names>I. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Смирнова Ирина Олеговна - доктор медицинских наук, профессор кафедры инфекционных болезней, эпидемиологии и дерматовенерологии Санкт-Петербургский ГУ, врач-дерматовенеролог городского центра дерматологии и венерологии Кожно-венерологический диспансер № 10 – КДВ.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Smirnova Irina O. - DM Sci (habil.), professor at Dept of Infectious Diseases, Epidemiology and Dermatovenereology Saint Petersburg SU, dermatovenereologist Dermatovenerologic Dispensary No. 10 – CDV.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный университет»; ФГБВОУ ВО «Военно-медицинская академия имени С.М. Кирова» Минобороны России; СПб ГБУЗ «Кожно-венерологический диспансер № 10 – Клиника дерматологии и венерологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State University; Military Medical Academy n. a. S.M. Kirov; Dermatovenerologic Dispensary No. 10 – Clinic of Dermatology and Venereology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>01</day><month>05</month><year>2023</year></pub-date><volume>0</volume><issue>5</issue><issue-title>Дерматология (1)</issue-title><fpage>49</fpage><lpage>52</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Владимирова И.С., Смирнова И.О., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Владимирова И.С., Смирнова И.О.</copyright-holder><copyright-holder xml:lang="en">Vladimirova I.S., Smirnova I.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/3072">https://www.med-alphabet.com/jour/article/view/3072</self-uri><abstract><p>Поражение кожи лица при псориазе, одном из наиболее распространенных дерматозов, традиционно считают относительно редким проявлением заболевания, особенно у взрослых больных, однако, по современным данным, оно наблюдается не менее чем у 40 % пациентов. Считают, что поражение кожи лица более характерно для пациентов молодого возраста с тяжелым распространенным поражением кожи, вовлечением ногтевых пластинок и затяжным течением. Локализация высыпаний на коже лица – в косметически и социально-значимой зоне – сопровождается значительными нарушениями качества жизни пациентов. Лечение псориаза лица представляет сложности, а алгоритмов ведения пациентов с псориатическим поражением на лице разработано мало. Мы представляем пациента, больного псориазом с вовлечением кожи лица, которое впервые сформировалось после отмены системной терапии ингибитором ИЛ-17А (иксекизумабом). В ходе наблюдения за пациентом возникла необходимость повторного назначения системной биологической терапии с потенциальным риском эффекта ускользания. В статье мы обсуждаем клинические проявления псориаза лица и влияние на качество жизни пациентов. Представлено описание наблюдения пациента с поражением кожи лица при тяжелом бляшечном псориазе и роли биологической терапии в этом направлении.</p></abstract><trans-abstract xml:lang="en"><p>Facial skin lesions in psoriasis, one of the most common dermatoses, are traditionally considered a relatively rare manifestation of the disease, especially in adult patients, but according to modern data, it is observed in at least 40 % of patients. It is believed that facial skin lesions are more typical for young patients with severe widespread skin lesions, involvement of the nail plates and a protracted course. Localization of rashes on the skin of the face – in a cosmetically and socially significant area – is accompanied by significant impairments in the quality of life of patients. The treatment of facial psoriasis is difficult, and few algorithms have been developed for the management of patients with facial psoriatic lesions. We present a patient with psoriasis involving facial skin that first developed after discontinuation of systemic therapy with an IL-17A inhibitor (ixekizumab). During the follow-up of the patient, it became necessary to re-administer systemic biological therapy with the potential risk of an escape effect. In the article, we discuss the clinical manifestations of facial psoriasis and the impact on the quality of life of patients. A description of the observation of a patient with lesions of the facial skin in severe plaque psoriasis and the role of biological therapy in this direction is presented.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>псориаз</kwd><kwd>псориаз лица</kwd><kwd>биологическая терапия</kwd><kwd>эффективность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>psoriasis</kwd><kwd>facial psoriasis</kwd><kwd>biological therapy</kwd><kwd>effectiveness</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology. 2006; 212: 327–337.</mixed-citation><mixed-citation xml:lang="en">Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology. 2006; 212: 327–337.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018 Aug 14. Epub ahead of print. DOI: 10.1007/s12016–018–8702–33.</mixed-citation><mixed-citation xml:lang="en">Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018 Aug 14. Epub ahead of print. DOI: 10.1007/s12016–018–8702–33.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Chiricozzi A, Saraceno R, Chimenti MS, et al. Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? Expert Opin Ther Targets. 2014; 18 (5): 513–525.</mixed-citation><mixed-citation xml:lang="en">Chiricozzi A, Saraceno R, Chimenti MS, et al. Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? Expert Opin Ther Targets. 2014; 18 (5): 513–525.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lowes MA, Russell CB, Martin DA, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013; 34: 174–181.</mixed-citation><mixed-citation xml:lang="en">Lowes MA, Russell CB, Martin DA, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013; 34: 174–181.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Schön Michael P., Boehncke W.-Henning (2005). Psoriasis, 352 (18), 1899–1912. DOI: 10.1056/nejmra041320.</mixed-citation><mixed-citation xml:lang="en">Schön Michael P., Boehncke W.-Henning (2005). Psoriasis, 352 (18), 1899–1912. DOI: 10.1056/nejmra041320.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Merola JF, Li T, Li W, et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol 2016; 41: 486–489.</mixed-citation><mixed-citation xml:lang="en">Merola JF, Li T, Li W, et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol 2016; 41: 486–489.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bernhard JD. Facial sparing in psoriasis. Int J Dermatol 1983; 22: 291–292.</mixed-citation><mixed-citation xml:lang="en">Bernhard JD. Facial sparing in psoriasis. Int J Dermatol 1983; 22: 291–292.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Farber EM. Facial psoriasis. Cutis. 1992 Jul; 50 (1): 25–8. PMID: 1516375.</mixed-citation><mixed-citation xml:lang="en">Farber EM. Facial psoriasis. Cutis. 1992 Jul; 50 (1): 25–8. PMID: 1516375.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">van de Kerkhof PC, Murphy GM, Austad J, Ljungberg A, Cambazard F, Duvold LB. Psoriasis of the face and flexures. J Dermatolog Treat. 2007; 18 (6): 351–60. DOI: 10.1080/09546630701341949. PMID: 17907013</mixed-citation><mixed-citation xml:lang="en">van de Kerkhof PC, Murphy GM, Austad J, Ljungberg A, Cambazard F, Duvold LB. Psoriasis of the face and flexures. J Dermatolog Treat. 2007; 18 (6): 351–60. DOI: 10.1080/09546630701341949. PMID: 17907013</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Потекаев Н. Н., Круглова Л. С. Псориатическая болезнь. Москва. МДВ. 2014. 264 с.</mixed-citation><mixed-citation xml:lang="en">Potekaev N. N., Kruglova L. S. Psoriatic disease. Moscow. MDV. 2014. 264 p.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Canpolat F., Cemil B. C., Eskioglu F., &amp; Akis H. K. (2008). Isfacial involvement a sign of severe psoriasis? European Journal of Dermatology, 18 (2), 169–171.</mixed-citation><mixed-citation xml:lang="en">Canpolat F., Cemil B. C., Eskioglu F., &amp; Akis H. K. (2008). Isfacial involvement a sign of severe psoriasis? European Journal of Dermatology, 18 (2), 169–171.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Park J. Y. Rim J. H. Choe Y. B. Youn J. I. Facial psoriasis: Comparison of patients with and without facial involvement. J Am Acad Dermatol. 2004; 50: 582–584.</mixed-citation><mixed-citation xml:lang="en">Park J. Y. Rim J. H. Choe Y. B. Youn J. I. Facial psoriasis: Comparison of patients with and without facial involvement. J Am Acad Dermatol. 2004; 50: 582–584.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Passos A. N., de A. Rêgo V. R.P., Duarte G. V., Santos e Miranda R. C., de O. Rocha B. and de F.S.P. de Oliveira M. (2019). Facial involvement and the severity of psoriasis. Int J Dermatol, 58: 1300–1304. https://doi.org/10.1111/ijd.14492</mixed-citation><mixed-citation xml:lang="en">Passos A. N., de A. Rêgo V. R.P., Duarte G. V., Santos e Miranda R. C., de O. Rocha B. and de F.S.P. de Oliveira M. (2019). Facial involvement and the severity of psoriasis. Int J Dermatol, 58: 1300–1304. https://doi.org/10.1111/ijd.14492</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Beattie P. and Lewis-Jones M. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. British Journal of Dermatology, 2006. 155: 145–151. https://doi.org/10.1111/j.1365– 2133.2006.07185.x</mixed-citation><mixed-citation xml:lang="en">Beattie P. and Lewis-Jones M. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. British Journal of Dermatology, 2006. 155: 145–151. https://doi.org/10.1111/j.1365– 2133.2006.07185.x</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Y. H. Liao; H. C. Chiu; Y. S. Tseng; T. F. Tsai (2007). Comparison of cutaneous tolerance and efficacy of calcitriol 3 μg g-1 ointment and tacrolimus 0•3 mg g-1 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: A double-blind, randomized controlled trial., 157 (5), 1005–1012. DOI: 10.1111/j.13652133.2007.08201.x.</mixed-citation><mixed-citation xml:lang="en">Y. H. Liao; H. C. Chiu; Y. S. Tseng; T. F. Tsai (2007). Comparison of cutaneous tolerance and efficacy of calcitriol 3 μg g-1 ointment and tacrolimus 0•3 mg g-1 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: A double-blind, randomized controlled trial., 157 (5), 1005–1012. DOI: 10.1111/j.13652133.2007.08201.x.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ortonne JP, Noerrelund KL, Papp K, Van Herpe L, Sebastian M, Herrera E, Bodalia B. Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body Eur J Dermatol. 2010 Sep-Oct; 20 (5): 585–9. DOI: 10.1684/ejd.2010.1013. Epub 2010 Aug 23. PMID: 20732849. Clinical Trial.</mixed-citation><mixed-citation xml:lang="en">Ortonne JP, Noerrelund KL, Papp K, Van Herpe L, Sebastian M, Herrera E, Bodalia B. Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body Eur J Dermatol. 2010 Sep-Oct; 20 (5): 585–9. DOI: 10.1684/ejd.2010.1013. Epub 2010 Aug 23. PMID: 20732849. Clinical Trial.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobi Arnd, Braeutigam Matthias, Mahler Vera, Schultz Erwin, Hertl Michael (2008). Pimecrolimus 1 Percent Cream in the Treatment of Facial Psoriasis: A 16-Week Open-Label Study. Dermatology, 216 (2), 133–136. DOI: 10.1159/000111510.</mixed-citation><mixed-citation xml:lang="en">Jacobi Arnd, Braeutigam Matthias, Mahler Vera, Schultz Erwin, Hertl Michael (2008). Pimecrolimus 1 Percent Cream in the Treatment of Facial Psoriasis: A 16-Week Open-Label Study. Dermatology, 216 (2), 133–136. DOI: 10.1159/000111510.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Zachary Cameron M. B., Belzer Annika, Fackler Nathan P., Shiu Jessica, Smith Janellen, Ghadially Ruby (2021). Facial psoriasis in a mask-like distribution. JAAD Case Reports, 7, 128–130. DOI: 10.1016/j.jdcr.2020.11.013.</mixed-citation><mixed-citation xml:lang="en">Zachary Cameron M. B., Belzer Annika, Fackler Nathan P., Shiu Jessica, Smith Janellen, Ghadially Ruby (2021). Facial psoriasis in a mask-like distribution. JAAD Case Reports, 7, 128–130. DOI: 10.1016/j.jdcr.2020.11.013.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Navarini AA, Poulin Y, Menter A, Gu Y, Teixeira Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis HD. J Drugs Dermatol. 2014 May; 13 (5): 554–62. PMID: 24809878. Clinical Trial.</mixed-citation><mixed-citation xml:lang="en">Navarini AA, Poulin Y, Menter A, Gu Y, Teixeira Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis HD. J Drugs Dermatol. 2014 May; 13 (5): 554–62. PMID: 24809878. Clinical Trial.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Paul C, Guenther L, Torii H, Sofen H, Burge R, Lin CY, Potts Bleakman A, Mallbris L, Poulin Y. Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. J Eur Acad Dermatol Venereol. 2018 Jan; 32 (1): 68–72. DOI: 10.1111/jdv.14581. Epub 2017 Oct 6. PMID: 28881462.</mixed-citation><mixed-citation xml:lang="en">Paul C, Guenther L, Torii H, Sofen H, Burge R, Lin CY, Potts Bleakman A, Mallbris L, Poulin Y. Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. J Eur Acad Dermatol Venereol. 2018 Jan; 32 (1): 68–72. DOI: 10.1111/jdv.14581. Epub 2017 Oct 6. PMID: 28881462.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Harrison PV, Walker GB. Facial psoriasis. Clin Exp Dermatol 1985; 10: 41–44.</mixed-citation><mixed-citation xml:lang="en">Harrison PV, Walker GB. Facial psoriasis. Clin Exp Dermatol 1985; 10: 41–44.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007; 9: 461–467.</mixed-citation><mixed-citation xml:lang="en">Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007; 9: 461–467.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Young Park J, Hyun Rim J, Beom Choe Y, Il Youn J. Facial psoriasis: Comparison of patients with and without facial involvement. J Am Acad Dermatol. 2004 Apr; 50 (4): 582–4. DOI: 10.1016/s0190–9622(03)02793–2. PMID: 15034507.</mixed-citation><mixed-citation xml:lang="en">Young Park J, Hyun Rim J, Beom Choe Y, Il Youn J. Facial psoriasis: Comparison of patients with and without facial involvement. J Am Acad Dermatol. 2004 Apr; 50 (4): 582–4. DOI: 10.1016/s0190–9622(03)02793–2. PMID: 15034507.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Passos AN, de A Rêgo VRP, Duarte GV, Santos E Miranda RC, de O Rocha B, de FSP de Oliveira M. Facial involvement and the severity of psoriasis. Int J Dermatol. 2019 Nov; 58 (11): 1300–1304. DOI: 10.1111/ijd.14492. Epub 2019 Jul 26. PMID: 31347152.</mixed-citation><mixed-citation xml:lang="en">Passos AN, de A Rêgo VRP, Duarte GV, Santos E Miranda RC, de O Rocha B, de FSP de Oliveira M. Facial involvement and the severity of psoriasis. Int J Dermatol. 2019 Nov; 58 (11): 1300–1304. DOI: 10.1111/ijd.14492. Epub 2019 Jul 26. PMID: 31347152.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Seung Man Woo; Jung Won Choi; Hyun Sun Yoon; Seong Jin Jo; Jai Il Youn (2008). Classification of facial psoriasis based on the distributions of facial lesions., 58 (6), 0–963. DOI: 10.1016/j.jaad.2008.02.006.</mixed-citation><mixed-citation xml:lang="en">Seung Man Woo; Jung Won Choi; Hyun Sun Yoon; Seong Jin Jo; Jai Il Youn (2008). Classification of facial psoriasis based on the distributions of facial lesions., 58 (6), 0–963. DOI: 10.1016/j.jaad.2008.02.006.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Park SY, Ha SH, Yu DS et al. Quantitative evaluation of severity in psoriatic lesions using three-dimensional morphometry. Exp Dermatol 2004; 13: 223–228.</mixed-citation><mixed-citation xml:lang="en">Park SY, Ha SH, Yu DS et al. Quantitative evaluation of severity in psoriatic lesions using three-dimensional morphometry. Exp Dermatol 2004; 13: 223–228.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Busse K, Liao W. Which Psoriasis Patients Develop Psoriatic Arthritis? Psoriasis Forum 2010; 16: 17–25.</mixed-citation><mixed-citation xml:lang="en">Busse K, Liao W. Which Psoriasis Patients Develop Psoriatic Arthritis? Psoriasis Forum 2010; 16: 17–25.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Syed Nong Chek SR, Robinson S, Mohd AA, Baharum N. Clinical characteristics of patients with facial psoriasis in Malaysia. Int J Dermatol 2016; 55: 1092–1095.</mixed-citation><mixed-citation xml:lang="en">Syed Nong Chek SR, Robinson S, Mohd AA, Baharum N. Clinical characteristics of patients with facial psoriasis in Malaysia. Int J Dermatol 2016; 55: 1092–1095.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Patrizi A, Venturi M, Scorzoni R, et al. Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: Risk factors for psoriatic arthritis in mild skin psoriasis? G Ital Dermatol Venereol 2014; 149: 177–184.</mixed-citation><mixed-citation xml:lang="en">Patrizi A, Venturi M, Scorzoni R, et al. Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: Risk factors for psoriatic arthritis in mild skin psoriasis? G Ital Dermatol Venereol 2014; 149: 177–184.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Круглова Л. С., Хотко А. А. Иммуногенность препаратов биологической терапии. Эффективная фармакотерапия. Дерматовенерология и дерматокосметология. № 2. 2018. С. 12–19.</mixed-citation><mixed-citation xml:lang="en">Kruglova L. S., Khotko A. A. Immunogenicity of biological therapy preparations. effective pharmacotherapy. Dermatovenereology and dermatocosmetology. No. 2. 2018. P. 12–19.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Круглова Л. С., Бакулев А. Л., Коротаева Т. В., Лила А. М., Переверзева Н. О. Псориаз. ГЭОТАР-Медиа. 2022. 328 с.</mixed-citation><mixed-citation xml:lang="en">Kruglova L. S., Bakulev A. L., Korotaeva T. V., Lila A. M., Pereverzeva N. O. Psoriasis. GEOTAR-Media. 2022. 328 p.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Sarma N. Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis. Indian J Dermatol 2017; 62: 113–122.</mixed-citation><mixed-citation xml:lang="en">Sarma N. Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis. Indian J Dermatol 2017; 62: 113–122.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Dopytalska Klaudia, et al. Psoriasis in special localizations. Reumatologia / Rheumatology, Vol. 56, No. 6, 2018, pp. 392–398. DOI: 10.5114/reum.2018.80718.</mixed-citation><mixed-citation xml:lang="en">Dopytalska Klaudia, et al. Psoriasis in special localizations. Reumatologia / Rheumatology, Vol. 56, No. 6, 2018, pp. 392–398. DOI: 10.5114/reum.2018.80718.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Круглова Л. С., Руднева Н. С., Бакулев А. Л., Хотко А. А. Инверсный псориаз и псориаз «трудных» локализаций: эффективность нетакимаба. Медицинский алфавит. 2022; 1 (27): 14–20. https://doi.org/10.33667/2078–5631–2022–27–14–20.</mixed-citation><mixed-citation xml:lang="en">Kruglova L. S., Rudneva N. S., Bakulev A. L., Khotko A. A. Inverse psoriasis and psoriasis of «difficult» localizations: the effectiveness of netakimab. Medical Alphabet. 2022; 1 (27): 14–20. https://doi.org/10.33667/2078–5631–2022–27–14–20.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Хотко А. А., Круглова Л. С., Помазанова М. Ю., Хотко Р. А. Эффективность препарата нетакимаб в реальной клинической практике у пациентов с тяжелыми формами псориаза. Медицинский Алфавит. 2020. 6 (420). Том № 1. С. 28–34.</mixed-citation><mixed-citation xml:lang="en">Hotko A. A., Kruglova L. S., Pomazanova M. Yu., Hotko R. A. Efficacy of netakimab in real clinical practice in patients with severe forms of psoriasis. Medical Alphabet. 2020. 6 (420). Volume No. 1. P. 28–34.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
